• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension
【24h】

Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension

机译：盐酸盐+拉扎替昔洛氏组合在青光眼和眼高血压治疗中的疗效

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: The only evidence-based mechanism for prevention and treatment of glaucomatous optic neuropathy is decreasing the intraocular pressure (IOP). Prescribing multiple ocular hypotensive agents, such as the combination of carteolol and latanoprost, may synergistically improve IOP; however, doing so may increase the complexity of a medication regimen, in turn, impairing patient adherence. Fixed-combination glaucoma medications offer convenience and effectiveness. New to this class of glaucoma medication is fixed combination carteolol-latanoprost (FCCL). Area covered: This review intends to give the reader a better understanding of the efficacy of the combination of carteolol and latanoprost separately, and where FCCL fits into the vast medical arsenal of IOP drops. Furthermore, it outlines the particular pharmacologic mechanisms targeted, the pharmacokinetics, effectiveness, the advantages of fixed-combination administration, and tolerability. Expert opinion: The combination of carteolol and latanoprost, separately or in a fixed-combination, is more effective than either drug alone. Given the early stage in development of FCCL, it has yet to be determined how FCCL compares to other fixed-combination medications. However, pending further approval, fixed-combination carteolol-latanoprost may represent a reasonable alternative for a patient whose IOP is inadequately controlled on a prostaglandin analog alone and for whom a simplified combination is preferred.
机译：介绍：唯一的防治肺螨神经病变的基于证据和治疗的机制正在降低眼压（IOP）。规定多个眼睛低血压剂，如樱桃醇和拉坦斯洛斯（Latanoprost）的组合，可能协同改善IOP;然而，这样做可能会增加药物方案的复杂性，反过来损害患者依从性。固定组合青光眼药物提供便利性和有效性。这类青光眼药物的新功能是固定组合Carteolol-Latanoprost（FCCL）。涵盖的区域：本综述打算让读者更好地了解Cartoolol和Latanoprost的组合单独的疗效，以及FCCL符合IOP滴剂的广阔医用库。此外，它概述了靶向的特定药理学机制，药代动力学，有效性，固定组合给药的优点和耐受性。专家意见：用单独的药物，单独或固定组合的丁醇和拉巴洛刀的组合比单独的药物更有效。鉴于FCCL发展的早期阶段，尚未确定FCCL如何与其他固定组合药物进行比较。然而，待定的进一步批准，固定组合组合的Carteolol-Latanoprost可以代表一种合理的替代物，其患者IOP单独地在前列腺素类似物上不充分控制，并且对于其中优选简化组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号